BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

国际贸易 · 2014/4/72 分钟阅读

Certain Hemostatic Products and Components Thereof; Institution of Investigation Pursuant to 19 U.S.C. 1337

本地自动翻译 · 来源原始语言

摘要

Notice is hereby given that a complaint was filed with the U.S. International Trade Commission on February 28, 2014, under section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, on behalf of Baxter International Inc. of Deerfield, Illinois; Baxter Healthcare Corporation of Deerfield, Illinois; and Baxter Healthcare SA of Switzerland. A letter supplementing the Complaint was filed on March 19, 2014. The complaint alleges violations of section 337 based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain hemostatic products and components thereof by reason of infringement of certain claims of U.S. Patent No. 8,303,981 ("the '981 patent"); U.S. Patent No. 8,512,729 ("the '729 patent"); U.S. Patent No. 6,066,325 ("the '325 patent"); U.S. Patent No. 8,357,378 ("the '378 patent"); and U.S. Patent No. 8,603,511 ("the '511 patent"). The complaint further alleges that an industry in the United States exists as required by subsection (a)(2) of section 337. The complainants request that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cea

来源原始语言: Federal Register — International Trade Commission打开原始公告 →

探索专题

商业洞察 →